West Pharmaceutical Services (WST) Depreciation & Amortization (CF) (2009 - 2026)

West Pharmaceutical Services has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $44.6 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $44.6 million, up 14.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $174.1 million (up 11.46% YoY), and the FY2025 annual result was $168.6 million, up 11.07% from the prior year.
• Depreciation & Amortization (CF) came in at $44.6 million for Q1 2026 at West Pharmaceutical Services, down from $46.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $46.4 million in Q4 2025 to a low of $28.7 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $34.8 million (2023), against an average of $36.2 million.
• Across the five-year window, Depreciation & Amortization (CF) decreased 6.81% in 2022 and gained 20.42% in 2023, its largest moves.
• West Pharmaceutical Services' Depreciation & Amortization (CF) stood at $30.1 million in 2022, then climbed by 14.95% to $34.6 million in 2023, then rose by 15.03% to $39.8 million in 2024, then advanced by 16.58% to $46.4 million in 2025, then declined by 3.88% to $44.6 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $44.6 million (Q1 2026), $46.4 million (Q4 2025), and $42.3 million (Q3 2025), per Business Quant data.